A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1
(PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors
Category & Conditions: Cancer
Medicine: ARRY-382 (PF-07265804)
ClinicalTrials.gov Identifier (NCT): NCT02880371
Protocol ID: C4261001
PrintDownloadOpen Plain Language Summary Result: Click here